CJC-1295 + Ipamorelin Blend

CJC-1295 + Ipamorelin Blend combines a long-acting GHRH analog with a selective GHRP for synergistic growth hormone release. This combination produces amplified, sustained GH elevation.

Mechanism of Action

CJC-1295 is a tetrasubstituted form of GHRH(1-29) that produces dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 days or more after a single injection (Teichman et al., 2006). Ipamorelin is the first selective growth hormone secretagogue, displaying high GH releasing potency without releasing ACTH or cortisol—a selectivity for GH release similar to that displayed by GHRH (Raun et al., 1998). The combination produces synergistic amplification of pulsatile GH release.

Research Applications

• Synergistic GH release studies (Teichman et al., 2006)
• GHRH/GHRP combination research (Raun et al., 1998)
• IGF-1 elevation optimization
• GH axis amplification
• Body composition studies

Product Specifications

• Composition: CJC-1295 (no DAC) + Ipamorelin
• Purity: ≥99% each component
• Form: Lyophilized powder
• Storage: -20°C

References

1. Teichman SL, et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." J Clin Endocrinol Metab. 2006. PMID: 16352683
2. Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue." Eur J Endocrinol. 1998. PMID: 9849822